JP2022174082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022174082A5 JP2022174082A5 JP2022130994A JP2022130994A JP2022174082A5 JP 2022174082 A5 JP2022174082 A5 JP 2022174082A5 JP 2022130994 A JP2022130994 A JP 2022130994A JP 2022130994 A JP2022130994 A JP 2022130994A JP 2022174082 A5 JP2022174082 A5 JP 2022174082A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- composition according
- adalimumab
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 claims 44
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 229960002964 adalimumab Drugs 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 7
- 239000004094 surface-active agent Substances 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 6
- 239000007979 citrate buffer Substances 0.000 claims 5
- 239000012929 tonicity agent Substances 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 238000004848 nephelometry Methods 0.000 claims 1
- 238000010979 pH adjustment Methods 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000006432 protein unfolding Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000004879 turbidimetry Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14169755.7 | 2014-05-23 | ||
| EP14169755.7A EP2946767B1 (en) | 2014-05-23 | 2014-05-23 | Liquid pharmaceutical composition |
| JP2017513324A JP2017516848A (ja) | 2014-05-23 | 2015-05-15 | 液体医薬組成物 |
| JP2021055560A JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021055560A Division JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022174082A JP2022174082A (ja) | 2022-11-22 |
| JP2022174082A5 true JP2022174082A5 (https=) | 2023-01-27 |
Family
ID=50774706
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513324A Withdrawn JP2017516848A (ja) | 2014-05-23 | 2015-05-15 | 液体医薬組成物 |
| JP2021055560A Withdrawn JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
| JP2022130994A Pending JP2022174082A (ja) | 2014-05-23 | 2022-08-19 | 液体医薬組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513324A Withdrawn JP2017516848A (ja) | 2014-05-23 | 2015-05-15 | 液体医薬組成物 |
| JP2021055560A Withdrawn JP2021107399A (ja) | 2014-05-23 | 2021-03-29 | 液体医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10426833B2 (https=) |
| EP (4) | EP2946767B1 (https=) |
| JP (3) | JP2017516848A (https=) |
| CN (2) | CN111939257A (https=) |
| AU (3) | AU2015263247A1 (https=) |
| CA (2) | CA3104940A1 (https=) |
| CY (1) | CY1124493T1 (https=) |
| DK (3) | DK3145488T3 (https=) |
| ES (2) | ES2607489T3 (https=) |
| HK (1) | HK1231391A1 (https=) |
| HR (1) | HRP20201242T1 (https=) |
| HU (1) | HUE050779T2 (https=) |
| IL (2) | IL277241B (https=) |
| LT (1) | LT3145488T (https=) |
| PT (1) | PT3145488T (https=) |
| RS (1) | RS60801B1 (https=) |
| SI (1) | SI3145488T1 (https=) |
| SM (1) | SMT202000479T1 (https=) |
| WO (1) | WO2015177059A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050557A1 (en) * | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| CN105543204A (zh) * | 2015-12-30 | 2016-05-04 | 海口奇力制药股份有限公司 | 一种组合物及其应用、含有该组合物的稳定剂 |
| WO2017177160A1 (en) | 2016-04-07 | 2017-10-12 | Nevakar Llc | Formulation for use in a method of treatment of pain |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110831621A (zh) * | 2017-04-18 | 2020-02-21 | 雷迪博士实验室有限公司 | 稳定的液体药物组合物 |
| JP7249670B2 (ja) * | 2017-10-03 | 2023-03-31 | ネヴァカー インジェクテーブルズ インコーポレイテッド | アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法 |
| MX2017016884A (es) * | 2017-12-19 | 2019-06-20 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina anti-tnfa. |
| KR102921210B1 (ko) | 2018-07-20 | 2026-01-30 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 조성물 |
| MX2021000790A (es) * | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| EP4598575A1 (en) * | 2022-10-07 | 2025-08-13 | Annexon, Inc. | Formulations for anti-c1q antibodies |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6388197A (ja) | 1986-09-30 | 1988-04-19 | Tosoh Corp | モノクロナル抗体の安定化方法 |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| US5900404A (en) | 1997-08-15 | 1999-05-04 | Amgen Inc. | Chemical modification of proteins to improve biocompatibility and bioactivity |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| US8008447B2 (en) | 2004-07-23 | 2011-08-30 | Genentech, Inc. | Crystallization of antibody or fragment thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| NZ563580A (en) | 2005-06-07 | 2010-09-30 | Esbatech An Alcon Biomedical R | Stable and soluble antibodies inhibiting TNFaplha |
| TWI543768B (zh) * | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| EP2362767B1 (en) * | 2008-10-29 | 2017-12-06 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| MX2011011772A (es) * | 2009-05-04 | 2012-02-08 | Abbott Biotech Ltd | Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. |
| BR112012021576A2 (pt) * | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| SG190069A1 (en) | 2010-11-11 | 2013-06-28 | Abbvie Biotechnology Ltd | IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| CN113244374A (zh) | 2011-07-01 | 2021-08-13 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013164837A1 (en) * | 2012-03-07 | 2013-11-07 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
| US20150150982A1 (en) | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| WO2014039903A2 (en) | 2012-09-07 | 2014-03-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
| EP2914289B1 (en) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
| EP3466973A1 (en) | 2012-11-01 | 2019-04-10 | AbbVie Inc. | Stable dual variable domain immunoglobulin protein formulations |
| CN104707146B (zh) | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| IN2014MU01248A (https=) | 2014-04-02 | 2015-10-09 | Intas Pharmaceuticals Ltd | |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP3050557A1 (en) | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
-
2014
- 2014-05-23 EP EP14169755.7A patent/EP2946767B1/en not_active Not-in-force
- 2014-05-23 ES ES14169755.7T patent/ES2607489T3/es active Active
-
2015
- 2015-05-15 CN CN202010856565.5A patent/CN111939257A/zh active Pending
- 2015-05-15 RS RS20201035A patent/RS60801B1/sr unknown
- 2015-05-15 CA CA3104940A patent/CA3104940A1/en not_active Abandoned
- 2015-05-15 SI SI201531313T patent/SI3145488T1/sl unknown
- 2015-05-15 DK DK15723695.1T patent/DK3145488T3/da active
- 2015-05-15 HR HRP20201242TT patent/HRP20201242T1/hr unknown
- 2015-05-15 EP EP21175530.1A patent/EP3939566A1/en active Pending
- 2015-05-15 CN CN201580039972.4A patent/CN106535935A/zh active Pending
- 2015-05-15 EP EP20186550.8A patent/EP3741358A1/en not_active Withdrawn
- 2015-05-15 WO PCT/EP2015/060818 patent/WO2015177059A1/en not_active Ceased
- 2015-05-15 EP EP15723695.1A patent/EP3145488B1/en active Active
- 2015-05-15 LT LTEP15723695.1T patent/LT3145488T/lt unknown
- 2015-05-15 PT PT157236951T patent/PT3145488T/pt unknown
- 2015-05-15 HK HK17105117.8A patent/HK1231391A1/zh unknown
- 2015-05-15 US US15/313,487 patent/US10426833B2/en active Active
- 2015-05-15 SM SM20200479T patent/SMT202000479T1/it unknown
- 2015-05-15 AU AU2015263247A patent/AU2015263247A1/en not_active Abandoned
- 2015-05-15 JP JP2017513324A patent/JP2017516848A/ja not_active Withdrawn
- 2015-05-15 ES ES15723695T patent/ES2815598T3/es active Active
- 2015-05-15 IL IL277241A patent/IL277241B/en unknown
- 2015-05-15 HU HUE15723695A patent/HUE050779T2/hu unknown
- 2015-05-15 CA CA2948746A patent/CA2948746C/en active Active
-
2016
- 2016-11-22 IL IL249116A patent/IL249116B/en active IP Right Grant
-
2019
- 2019-09-26 US US16/584,418 patent/US20200155677A1/en not_active Abandoned
-
2020
- 2020-04-08 DK DKBA202000030U patent/DK202000030Y3/da active IP Right Grant
- 2020-05-14 DK DKBA202000038U patent/DK202000038Y3/da not_active IP Right Cessation
- 2020-06-26 AU AU2020204269A patent/AU2020204269B2/en not_active Ceased
- 2020-09-08 CY CY20201100843T patent/CY1124493T1/el unknown
- 2020-12-10 AU AU2020286276A patent/AU2020286276B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 JP JP2021055560A patent/JP2021107399A/ja not_active Withdrawn
-
2022
- 2022-08-19 JP JP2022130994A patent/JP2022174082A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022174082A5 (https=) | ||
| JP5946448B2 (ja) | 持続型ヒト成長ホルモン結合体液状製剤 | |
| JP7446356B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP2021523162A5 (https=) | ||
| CN102946858B (zh) | 含有免疫球蛋白Fc的多肽的液体制剂 | |
| EP2726090B1 (en) | Arginine - free tnfr : fc- fusion polypeptide compositions | |
| JP2023060016A (ja) | モノクローナル抗体製剤 | |
| JP2024099682A5 (https=) | ||
| JP2013543505A5 (https=) | ||
| CN104011073B (zh) | 使用氨基酸稳定的依那西普制剂 | |
| TWI848956B (zh) | 包含vegf拮抗物之液體組成物 | |
| US11696951B2 (en) | Viscosity-reducing compounds for protein formulations | |
| CN102753147B (zh) | 长效红细胞生成素缀合物的液体制剂 | |
| TW202146049A (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| BR112012017979B1 (pt) | Formulações líquidas para conjugado de g-csf de ação prolongada | |
| JPWO2019217927A5 (https=) | ||
| CN101312744A (zh) | 免疫球蛋白融合蛋白制剂 | |
| JP2019536761A5 (https=) | ||
| AU7824201A (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| CA3129181C (en) | Excipient compounds for biopolymer formulations | |
| RU2016150640A (ru) | Жидкая фармацевтическая композиция | |
| CN101631563A (zh) | 含有流感疫苗的冻干制剂及其制备方法 | |
| JP2019517513A (ja) | 眼科用医薬組成物 | |
| JP2016088897A (ja) | エタネルセプトの凍結乾燥製剤 | |
| CN112672734A (zh) | 包含蛋白质和聚烷氧基脂肪酰基表面活性剂的组合物 |